Supplementary Table 1 - 9 and Figures 1 - 14 from Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer
Supplementary Figure 1: OMI endpoints of organoids derived from a trastuzumabresponsive xenograft tumor. Supplementary Figure 2: Population modeling identifies heterogeneous drug responses of BT474 cells. Supplementary Figure 3: OMI endpoints of organoids derived from a trastuzumab-resistant xenograft tumor. Supplementary Figure 4: Population modeling identifies heterogeneous drug responses of HR6 cells. Supplementary Figure 5: Population modeling identifies heterogeneous drug responses of organoids from patient sample #1 (ER+/HER2-). Supplementary Figure 6: OMI endpoints of organoids derived from a ER+ primary tumor. Supplementary Figure 7: Population modeling identifies heterogeneous drug responses of organoids from patient sample #2 (ER+/HER2-). Supplementary Figure 8: OMI endpoints of organoids derived from a second ER+ primary tumor. Supplementary Figure 9: Population modeling identifies heterogeneous drug responses of organoids from patient sample #3 (ER+/HER2-). Supplementary Figure 10: Population modeling identifies heterogeneous drug responses of organoids from patient sample #4 (ER+/HER2-). Supplementary Figure 11: OMI endpoints of organoids derived from a third ER+ primary tumor. Supplementary Figure 12: OMI endpoints of organoids derived from a fourth ER+ primary tumor. Supplementary Figure 13: OMI endpoints of organoids derived from a HER2+ primary tumor. Supplementary Figure 14: OMI endpoints of organoids derived from a TNBC primary tumor. Supplementary Table 1: NADH and FAD lifetime component values of BT474-xenograft derived organoids. Supplementary Table 2: NADH and FAD lifetime component values. Supplementary Table 3: Grade, proliferation rate, estrogen receptor expression, progesterone receptor expression, and HER2 receptor. Supplementary Table 4: NADH and FAD lifetime component values Supplementary Table 5: NADH and FAD lifetime component values of organoids. Supplementary Table 6: NADH and FAD lifetime component values. Supplementary Table 7: NADH and FAD lifetime component values of organoids derived from a fourth ER+ primary tumor. Supplementary Table 8: NADH and FAD lifetime component values of organoids derived from a HER2+ primary tumor. Supplementary Table 9: NADH and FAD lifetime component values of organoids derived from a TNBC primary tumor.